Regenxbio (RGNX) Operating Expenses (2014 - 2025)

Regenxbio's Operating Expenses history runs 12 years deep, the most recent figure standing at $308.3 million for Q4 2025.

• In Q4 2025, Operating Expenses rose 324.83% year-over-year to $308.3 million; the TTM figure through Dec 2025 stood at $475.0 million (up 98.98% YoY), while the FY2025 annual figure was $331.6 million, up 4.73% from the prior year.
• Operating Expenses was $308.3 million for Q4 2025 at Regenxbio, up from $82.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $308.3 million in Q4 2025 to a low of -$276.5 million in Q4 2023.
• Historically, Operating Expenses has averaged $69.8 million across 5 years, with a median of $85.2 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses tumbled 410.26% in 2023, then jumped 4912.06% in 2025.
• A 5-year view of Operating Expenses shows it stood at $85.1 million in 2021, then grew by 4.77% to $89.1 million in 2022, then sank by 410.26% to -$276.5 million in 2023, then surged by 126.25% to $72.6 million in 2024, then soared by 324.83% to $308.3 million in 2025.
• The last three Operating Expenses figures came in at $308.3 million (Q4 2025), $82.1 million (Q3 2025), and $7.6 million (Q2 2025), per Business Quant data.